Aug 2026· Clinical Autonomic Research· 1 citation· 8 references
Medicine
TL;DR
Cutaneous phosphorylated alpha-synuclein deposition increased over time and correlated with objective orthostatic hypotension and autonomic symptom burden in early synucleinopathy, and may serve as a minimally invasive tool to support diagnosis, monitor progression, and stratify clinical trial participants.
Abstract
Purpose: Multiple system atrophy is a progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. Phosphorylated alpha-synuclein in skin nerves has emerged as a promising biomarker, but longitudinal studies remain limited. This study evaluated changes in cutaneous alpha-synuclein deposition over time, its association with autonomic dysfunction, and its concordance with seed amplification assay findings. Methods: Seventeen participants with probable multiple system atrophy were followed for twelve months with clinical assessments, skin biopsies from posterior cervical and distal thigh regions, standardized orthostatic vital signs, and cerebrospinal fluid biomarker collection. Phosphorylated alpha-synuclein deposition was quantified using immunofluorescence microscopy and correlated with autonomic measures and seed amplification assay results. Results: Cutaneous alpha-synuclein deposition increased from baseline to twelve months. Total deposition was associated with orthostatic systolic blood pressure drop (ρ = 0.80, p = 0.0001) and with higher scores on the Orthostatic Hypotension Questionnaire and Composite Autonomic Symptom Score. Posterior cervical deposition showed stronger autonomic associations than distal thigh. No associations were found with global disease severity or neurofilament light chain levels. Two participants with negative seed amplification assay results showed phosphorylated alpha-synuclein on skin biopsy. Conclusion: In this cohort, cutaneous phosphorylated alpha-synuclein increased over time and correlated with objective orthostatic hypotension and autonomic symptom burden in early synucleinopathy. Skin biopsy may serve as a minimally invasive tool to support diagnosis, monitor progression, and stratify clinical trial participants.
INTRODUCTION
Alpha-synucleinopathies are a group of disorders characterized by the accumulation of the pathological form of alpha-synuclein. This group comprises Parkinson's disease, Parkinson's disease dementia, multiple system atrophy, dementia with Lewy bodies, pure autonomic failure, and idiopathic REM sleep behavi...
Karol Kutyłowski, Piotr Alster, Natalia Madetko-Alster· Neurologia i Neurochirurgia...· 0 citations
Overall, α-synuclein represents a promising complementary marker in iNPH, with potential value in being taken into consideration during clinical evaluation and understanding disease heterogeneity.
Efstratios-Stylianos Pyrgelis, G. Paraskevas, Vasileios Constantinides et al.· Diagnostics· 0 citations
The association between MLR and the composite Frontal Network Score supports a link between systemic immune alterations and network-level neurodegeneration in PSP.
B. Migda, M. Kutyłowski, Natalia Madetko-Alster et al.· Neurology International· 0 citations
Introduction The neurodegenerative disorders characterized by deposition of phosphorylated alpha-synuclein (P-SYN) include Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies (DLB). Diagnosis of synucleinopathies in clinical practice has been enhanced by recent updates to diagnostic gu...
T. Levine, R. Freeman, N. Murray et al.· Frontiers in Neurology· 0 citations
Various categories of biomarkers, including protein aggregates, inflammation-related factors, oxidative stress markers, metabolomic and lipidomic signatures, genetic and epigenetic status, and PD-related exosomes are discussed, could serve as a diagnostic tool for PD and may provide predictive measures of disease outco...
Jerly Helan Mary Joseph, Mahesh Kandasamy· International review of neur...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.